Business
Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
- Data to be presented at International Shock Congress by sepsis thought leaders - TORONTO, June ...
About this update from Spectral Medical Inc
[{"type":"text","content":"\n\n\n\n- Data to be presented at International Shock Congress by sepsis thought\n\n\nleaders -\n\n\nTORONTO, June 26 /CNW/ - Spectral Diagnostics Inc. (TSX: SDI) today\nannounced the presentation of data that demonstrates the combined clinical\neffectiveness of its Endotoxin Activity Assay (EAA(TM)), the only FDA cleared\ndiagnostic for the measurement of endotoxin, to identify patients with\nelevated endotoxin levels and to guide endotoxin reducing strategies, such as\nToray Medical's therapeutic column, Toraymyxin(TM). The presentations will be\nmade at a symposium entitled "Blood Purification in the Treatment of Sepsis,"\nat the International Shock Congress in Cologne, Germany to be held from June\n28-July 2.\n\n\n"Several of the presentations at this important congress use data\ncollected with Spectral's EAA(TM) and highlight the value of our product, both\nindependently and in combination with anti-endotoxin therapies," said\nDr. Paul Walker, President and CEO of Spectral. "Increasingly, EAA(TM) and\nToray's therapeutic column, Toraymyxin(TM), which removes endotoxin from the\nbloodstream, are being recognized as a valuable combination for the diagnosis,\ntreatment and monitoring of patients with severe sepsis."\n\n\nThe "Blood Purification in the Treatment of Sepsis" symposium will be\nheld on July 1, from 8:30-10:00AM CEST. Speakers presenting data using EAA(TM)\ninclude Dr. David Klein of St. Michael's Hospital in Toronto, Canada, who will\ndeliver a presentation entitled, "The Endotoxin Activity Assay (EAA(TM)) as a\ndiagnostic tool for anti-endotoxin sepsis treatment". Dr. Eugen Faist of the\nUniversity of Munich in Germany will speak about, "Endotoxemia and immune\nprofiles of patients with acute sepsis due to major peritonitis". Information\non the meeting, including the full scientific program, can be seen at\nwww.shocksociety.org.\n\n\nAbout Spectral Diagnostics\n\n\nSpectral is a leader in the battle against sepsis. Spectral's lead\nproduct is its Endotoxin Activity Assay (EAA(TM)), the only FDA cleared assay\nfor the measurement of endotoxin. With the growing awareness for the role of\nendotoxemia in sepsis and the increasing number of therapies being developed\nfor this indication, Spectral is well-positioned to drive the adoption of the\nEAA(TM), whic...